The Lean Mass Question Separating Signal From Panic Muscle loss has become the most discussed long-term concern around GLP-1 therapy
In one standout phase 2 trial, retatrutide demonstrated up to 29% body weight loss over 68 weeks, resetting the standard for weight loss medications
External resources NEJM: Triple Hormone-Receptor Agonist Retatrutide for Obesity Phase 2 Trial PMC: Retatrutide - A Game Changer in Obesity Pharmacotherapy PMC: Efficacy and Safety of Retatrutide - Systematic Review and Meta-Analysis American Diabetes Association: Retatrutide Clinical Highlights Nature Medicine: Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease For researchers serious about optimizing their retatrutide protocols, SeekPeptides offers the most comprehensive resource available, with evidence-based guides, proven protocols, personalized dosing tools, and a community of thousands who have navigated these exact decisions
The halfway mark
What is lacking: Clinical trial data on the finished product
Furthermore, this novel concept suggests that the GLP-1 analog could spare the pasireotide-induced decrease in endogenous GLP-1 concentrations and recover insulin secretion suppressed by pasireotide through GLP-1R-Gs activation counteracting the SSTRs-Gi axis
